These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30867522)

  • 21. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.
    Chen X; Liu G; Wang K; Chen G; Sun J
    Oncotarget; 2017 Jul; 8(29):47831-47840. PubMed ID: 28599299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
    D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
    Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
    Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
    Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
    Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
    Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis.
    Sharma G; Whang EE; Ruan DT; Ito H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1229-37. PubMed ID: 26152276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review and meta-analysis of the outcomes following neoadjuvant therapy in upfront resectable gastric cancers compared to surgery alone in phase III randomised controlled trials.
    Lim Khai Shin A; Ho Si Ying A; Neo Hui Wen S; Yeo SC; Tay KV
    J Gastrointest Surg; 2023 Jun; 27(6):1261-1276. PubMed ID: 36882627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant therapy versus upfront resection for clinically "resectable" pancreatic cancer: The debate continues.
    Sarr MG; Behrns KE
    Surgery; 2020 Dec; 168(6):993. PubMed ID: 33066983
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
    Liu S; Li H; Xue Y; Yang L
    PLoS One; 2023; 18(9):e0290888. PubMed ID: 37672511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Carcinoma of the pancreas: current status of multimodal therapy].
    Keck T
    Zentralbl Chir; 2011 Aug; 136(4):352-8. PubMed ID: 21773958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
    di Sebastiano P; Grottola T; di Mola FF
    Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma.
    Blair AB; Sorber R; Rozich NS; Burkhart RA
    Pancreas; 2019 Sep; 48(8):973-984. PubMed ID: 31425483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
    Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
    Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
    BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis.
    Lee YS; Lee JC; Yang SY; Kim J; Hwang JH
    Sci Rep; 2019 Oct; 9(1):15662. PubMed ID: 31666626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials.
    Birrer DL; Golcher H; Casadei R; Haile SR; Fritsch R; Hussung S; Brunner TB; Fietkau R; Meyer T; Grützmann R; Merkel S; Ricci C; Ingaldi C; Di Marco M; Guido A; Serra C; Minni F; Pestalozzi B; Petrowsky H; DeOliveira M; Bechstein WO; Bruns CJ; Oberkofler CE; Puhan M; Lesurtel M; Heinrich S; Clavien PA
    Ann Surg; 2021 Nov; 274(5):713-720. PubMed ID: 34334656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.